Overview:
Rheumatoid arthritis is an autoimmune, inflammatory disease that causes chronic pain, swelling and loss in the functioning ability of joints. It occurs when the immune system attacks the synovium – the inner lining of membranes that surrounds the joints. In some patients, the antibodies also damage some body systems including the skin, heart, eyes, lungs and blood vessels. Prevalence of rheumatoid arthritis widely varies in different geographic region, the lowest rates is observed in the Asian countries and higher rates among some American populations. According to Centers for Disease Control and Prevention (CDC), the prevalence of rheumatoid arthritis in the United States is approximately 0.6% of total population. Generally rheumatoid arthritis affects at twice the rate in women as compared to men. Mostly rheumatoid arthritis affects among those in their sixties. According to World Health Organization (WHO), prevalence varies between 0.3% and 1% and is more common in developed countries.
There are many approaches used in treatment of rheumatoid arthritis such as drug therapy, rehabilitation and physical therapy, nutrition, psychosocial interventions, alternative treatment approaches and surgical interventions. Global rheumatoid arthritis therapeutics market is segmented on the basis of drug type such as Non-biologics and Biologic agent (Adalimumab, Infliximab and others). Non-biologics is sub-segmented as NSAIDs (Diclofenac, Ibuprofen and others), Disease-modifying antirheumatic drugs (DMARDs) (Methotrexate, Leflunomide and others) and steroids (Cortisone or Prednisone). Biologics, DMARDs and steroids slows the joint damage from rheumatoid arthritis, while NSAIDs only reduces pain and inflammation. Biologics are used in treatment of moderate to severe rheumatoid arthritis when patient does not respond adequately to other treatments.
The major growth drivers of the global rheumatoid arthritis therapeutic market includes, increase in geriatric population that will increase prevalence of rheumatoid arthritis, launch of novel therapeutic agents, higher prevalence rates among some American native populations and insurance coverage for high cost specialty drugs in developed countries. However, factors such as, inadequate insurance coverage for certain drugs in developing countries, non-availability of the treatment and patent expiration of some blockbuster drugs are the main restraints for the rheumatoid arthritis therapeutic market.
Some key Players in global rheumatoid arthritis therapeutic market are, Pfizer Inc., Bristol Myers Squibb, Abbvie Inc., Ucb Pharma, Genentech, Janssen Pharmaceutical, Immunex Corp., Medac Pharma, Mallinckrodt, Novartis and others. Key players having drugs in the pipeline are Boehringer Ingelheim, Pfizer Inc., Astrazeneca Pharma, MedImmune, Novartis, Biogen, Eli Lilly And Company, Astellas Pharma, Roche, Vertex Pharmaceuticals and others.
The Global Rheumatoid Arthritis Therapeutics Market is segmented on the following bases:
· Global Rheumatoid Arthritis Therapeutic Market Revenue (USD Mn), By drug type, 2016-2024
o Non-biologics
o Biologic agent
· Global Rheumatoid Arthritis Therapeutic Market Revenue (USD Mn), By Geography, 2016-2024
§ North America
o US
o Canada
§ Europe
o UK
o Germany
o Rest of Europe
§ Asia-Pacific
o Japan
o China
o Rest of APAC
§ Latin America
§ Middle East and Africa
Key Players Identified for Global Rheumatoid Arthritis Therapeutics Market Include:
Pfizer Inc., Bristol Myers Squibb, Abbvie Inc., Astrazeneca Pharma, Ucb Pharma, Genentech, Janssen Pharmaceutical, Immunex Corp., Medac Pharma, Boehringer Ingelheim, Novartis, Biogen, Eli Lilly And Company, Astellas Pharma, Mallinckrodt, Roche, Vertex Pharmaceuticals and other.
This report offers:
